Navigation Links
Novel Technology Breaks Through Cancer Pain
Date:8/19/2007

MORRISVILLE, N.C., Aug. 16 /PRNewswire/ -- Cancer patients fraught with flare-ups of pain, or breakthrough pain, may soon receive some assistance in the form of a new easy-to-use oral drug delivery system developed by BioDelivery Sciences designed to quickly deliver pain medication.

Cancer patients frequently experience two types of pain: persistent and breakthrough. Persistent cancer pain is characterized as continuous pain present for long periods of time, and often most of the day. Persistent pain is treated by daily or regular doses of pain medication.

Breakthrough pain is a brief and often severe shooting of pain that "breaks through" a patient's continuous medication for persistent pain. Breakthrough pain often has a rapid onset and lasts a short duration of time. It is called breakthrough pain because it "breaks through" a regular pain medicine schedule.

"Breakthrough pain is caused either by the cancer itself or the cancer treatment. For some patients, the pain is connected to certain activities, such as walking or dressing. For others, it occurs unexpectedly," says Dr. Andrew Finn, BioDelivery Sciences' VP of Product Development.

One breakthrough pain medication is the opiate fentanyl. Fentanyl is a potent opioid analgesic (painkiller) first developed in the 1950s, and long in use by the medical community for controlling various types of pain.

The next generation product able to quickly deliver fentanyl for the treatment of cancer breakthrough pain is a patient-friendly, small oral adhesive disc called BEMA Fentanyl, which has recently completed Phase III trials by BioDelivery Sciences. The BEMA technology is a very small layered disc that is applied to a mucosal surface (inner lining of the mouth) in a similar way a transdermal disc is applied to the skin.

The small disc is composed of an adhesive layer and a non-adhesive backing layer. The disc adheres to the inside cheeks and delivers the dose of medication quic
'/>"/>

SOURCE BioDelivery Sciences

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...ark Laboratories, L.C., a,privately-owned biopharm...of enrollment into its Phase II clinical trial to ...n combination with standard of care therapy in,U.S... have previously,failed to respond to the standard...e company expects to announce interim data results...
(Date:5/21/2008)...oup of Leading Cancer Centers ...y 21 /- Endocare, Inc.,(Nas... focused on the,development of minimally invasive ... radiologists for tissue and tumor ablation, annou... method of freezing cancerous tumors,to destroy th...
(Date:5/20/2008)...positive results of nine month,PAINT trials for Dr...esults unveiled during plenary session of Eu...wswire/ -- Sahajanand Medical Technologies,Pvt. Lt...facturer of,drug-eluting stents, welcomed the posi...onths results of PAINT trial (PercutAneous INTerve...
(Date:5/20/2008)...igestive Disease Week -, CAMBRIDGE, Mass. and NEW...harmaceuticals, Inc. (formerly Microbia, Inc.) and...ounced the presentation of data,from a Phase 2b ra...ssessing the safety and efficacy of linaclotide in... of these data indicate that linaclotide met its,p...
Breaking Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Secondhand smoke increases teen test failure 1648 1Secondhand smoke increases teen test failure 1648 2Spectral partner launches EAA 28TM 29 Rapid Sepsis Diagnostic in Germany 711 1Spectral partner launches EAA 28TM 29 Rapid Sepsis Diagnostic in Germany 711 2Vical Licensee Sanofi aventis Initiates Phase 3 Trial to Reduce Amputations 336 1Vical Licensee Sanofi aventis Initiates Phase 3 Trial to Reduce Amputations 336 2Vical Licensee Sanofi aventis Initiates Phase 3 Trial to Reduce Amputations 336 3MedAire to Provide Medical Training for Bombardier Safety Standdown 1644 1MedAire to Provide Medical Training for Bombardier Safety Standdown 1644 2MedAire to Provide Medical Training for Bombardier Safety Standdown 1644 3
...ylene Glycol,(DEG) Remains a Potential Health Haza...he U.S. Food and Drug,Administration (FDA) is warn...repackers, and health professionals who compound,m...hat glycerin, a,sweetener commonly used worldwide ...roducts, is not contaminated with diethylene,glyco...
...nnovations and a Health Conscious,Public?, WASHING... Food,and Drug Administration (FDA) must adapt to ...lthcare, Commissioner Andrew von,Eschenbach told a...,Annual Conference April 12 in Bethesda, Md. , FDA...ited,financial and personnel resources to deal wit...
Other Medicine Technology:FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations,FDA Regulations 2
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
... survey, biting a bar of chocolate every day is co...h chocolates are high in fat and sugar, it has lon..., recent evidence suggests that, like other plant ...xidants, which can protect from chronic disease. ...
...tudy which suggests hormone suppression therapy co...ncer patient's chances of living free of the disea...y Hospital, examined the potential benefits of sup...e more commonly known male hormone testosterone, a...
... amount of fluids should be taken, in order to rep...er is far better than 'energy' drinks for keeping ...is maximum need for fluids,// henceforth, you'll b...ls topped up with regular drinks. There are a lot ...
...ch are protective substances, produced by the body...m kill the TB bacteria, researchers in the UK repo... journal Nature Medicine,// these heat-shock prote...body help cells survive stressful times and bolste...
Other Medicine News:Health News:Hormone Therapy applicable for Prostate Cancer 2
Cushing bayonet forceps. Insulated.
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size.
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile
Medicine Products: